Cargando…
Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy
Patient‐derived cancer cells (PDCs) and patient‐derived xenografts (PDXs) are often used as tumor models, but have many shortcomings. PDCs not only lack diversity in terms of cell type, spatial organization, and microenvironment but also have adverse effects in stem cell cultures, whereas PDX are ex...
Autores principales: | Qu, Jingjing, Kalyani, Farhin Shaheed, Liu, Li, Cheng, Tianli, Chen, Lijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696219/ https://www.ncbi.nlm.nih.gov/pubmed/34713636 http://dx.doi.org/10.1002/cac2.12224 |
Ejemplares similares
-
Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications
por: Chen, Lijun, et al.
Publicado: (2022) -
Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study
por: Qu, Jingjing, et al.
Publicado: (2022) -
Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
por: Qu, Jingjing, et al.
Publicado: (2022) -
Intestinal Organoids—Current and Future Applications
por: Meneses, Andre M. C., et al.
Publicado: (2016) -
Palmitoylation in Crohn’s disease: Current status and future directions
por: Cheng, Wei-Xin, et al.
Publicado: (2021)